HU228957B1 - Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response - Google Patents

Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response Download PDF

Info

Publication number
HU228957B1
HU228957B1 HU0401392A HUP0401392A HU228957B1 HU 228957 B1 HU228957 B1 HU 228957B1 HU 0401392 A HU0401392 A HU 0401392A HU P0401392 A HUP0401392 A HU P0401392A HU 228957 B1 HU228957 B1 HU 228957B1
Authority
HU
Hungary
Prior art keywords
hla
treatment
cells
goat
hiv
Prior art date
Application number
HU0401392A
Other languages
English (en)
Hungarian (hu)
Inventor
Angus G Dalgleish
Martin Cadogan
Jonathan Heeney
Stanley D T White
Original Assignee
Aimsco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116151A external-priority patent/GB0116151D0/en
Priority claimed from GB0128638A external-priority patent/GB0128638D0/en
Priority claimed from GBGB0201896.8A external-priority patent/GB0201896D0/en
Priority claimed from GB0207509A external-priority patent/GB0207509D0/en
Application filed by Aimsco Ltd filed Critical Aimsco Ltd
Publication of HUP0401392A2 publication Critical patent/HUP0401392A2/hu
Publication of HUP0401392A3 publication Critical patent/HUP0401392A3/hu
Publication of HU228957B1 publication Critical patent/HU228957B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
HU0401392A 2001-07-02 2002-07-02 Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response HU228957B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0116151A GB0116151D0 (en) 2001-07-02 2001-07-02 Therapeutic agent
GB0128638A GB0128638D0 (en) 2001-11-29 2001-11-29 Therapeutic agent
GBGB0201896.8A GB0201896D0 (en) 2002-01-28 2002-01-28 Treatment
GB0207509A GB0207509D0 (en) 2002-03-28 2002-03-28 Therapeutic agent
PCT/GB2002/003037 WO2003004049A2 (en) 2001-07-02 2002-07-02 Use of polyclonal anti-hiv goat serum as a therapeutic agent

Publications (3)

Publication Number Publication Date
HUP0401392A2 HUP0401392A2 (hu) 2004-10-28
HUP0401392A3 HUP0401392A3 (en) 2012-09-28
HU228957B1 true HU228957B1 (en) 2013-07-29

Family

ID=27447968

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401392A HU228957B1 (en) 2001-07-02 2002-07-02 Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response

Country Status (18)

Country Link
US (4) US20100291102A1 (https=)
EP (1) EP1404367B1 (https=)
JP (2) JP5014562B2 (https=)
KR (2) KR20040030786A (https=)
CN (1) CN100423776C (https=)
AT (1) ATE478681T1 (https=)
AU (1) AU2002317285B2 (https=)
BR (1) BR0210772A (https=)
CA (1) CA2452986C (https=)
DE (1) DE60237447D1 (https=)
DK (1) DK1404367T3 (https=)
EA (1) EA013517B1 (https=)
HU (1) HU228957B1 (https=)
IL (2) IL159682A0 (https=)
MX (1) MXPA04000147A (https=)
NZ (1) NZ530393A (https=)
PL (1) PL216741B1 (https=)
WO (1) WO2003004049A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum
SG156658A1 (en) * 2004-04-05 2009-11-26 Aimsco Ltd Treatment of diseases
BRPI0513062A (pt) * 2004-07-08 2008-04-22 Aimsco Ltd composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença
GB0415359D0 (en) * 2004-07-08 2004-08-11 Aimsco Ltd Medicament
GB0502083D0 (en) * 2005-02-02 2005-03-09 Aimsco Ltd Bioactive compounds
GB0508153D0 (en) * 2005-04-22 2005-06-01 Aimsco Ltd Therapeutic agent
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
ES2536401T3 (es) * 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
US8734852B2 (en) * 2011-11-30 2014-05-27 Manu Chaudhary Parenteral controlled release formulations of NSAID's
CA2877562A1 (en) 2012-06-25 2014-01-03 Aimsco Limited Formulation comprising crh and alpha-2 macroglobulin
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
SG11201811323XA (en) 2017-01-31 2019-01-30 Illumina Inc Fluidic devices and methods of manufacturing the same
CN117538549A (zh) * 2023-09-27 2024-02-09 上海交通大学医学院附属瑞金医院 一种评估血浆置换清除dsa临床疗效的预测体系

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
SK80697A3 (en) * 1994-12-23 1997-12-10 Om Lab Sa Use of mhc-ii binding molecules
US6328962B2 (en) * 1995-06-07 2001-12-11 Aventis Pasteur Limited Method for delivery of antigens to selected cells of the immune system using chimeric antibodies
WO1997002839A1 (en) * 1995-07-13 1997-01-30 Gkc Research, Inc. Viral suppression, treatment and prevention of viral infections
WO1997039119A1 (en) * 1996-04-15 1997-10-23 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
GB9619894D0 (en) * 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
IL146566A0 (en) * 1999-05-24 2002-07-25 Sankyo Co A pharmaceutical composition containing anti-fas antibody
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2001060156A1 (en) * 2000-02-14 2001-08-23 Gary R. Davis, M.D., L.L.C. Neutralizing antibody and immunomodulatory enhancing compositions
EP1156060B1 (en) * 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
WO2002007760A2 (en) * 2000-07-21 2002-01-31 Ice Biologics Limited Therapeutic agent against aids comprising anti hiv goat antibody
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent

Also Published As

Publication number Publication date
MXPA04000147A (es) 2005-01-07
US20130230600A1 (en) 2013-09-05
EA200400134A1 (ru) 2004-08-26
ATE478681T1 (de) 2010-09-15
BR0210772A (pt) 2004-07-20
EP1404367B1 (en) 2010-08-25
PL216741B1 (pl) 2014-05-30
HUP0401392A2 (hu) 2004-10-28
CN100423776C (zh) 2008-10-08
EA013517B1 (ru) 2010-06-30
US20120100156A1 (en) 2012-04-26
KR20090046970A (ko) 2009-05-11
WO2003004049A3 (en) 2003-04-24
NZ530393A (en) 2006-10-27
DK1404367T3 (da) 2010-12-13
IL159682A0 (en) 2004-06-20
US20160002320A1 (en) 2016-01-07
CA2452986C (en) 2011-11-01
WO2003004049A2 (en) 2003-01-16
AU2002317285B2 (en) 2007-05-24
CN1620311A (zh) 2005-05-25
JP2004536105A (ja) 2004-12-02
DE60237447D1 (de) 2010-10-07
JP2009149693A (ja) 2009-07-09
CA2452986A1 (en) 2003-01-16
HUP0401392A3 (en) 2012-09-28
KR20040030786A (ko) 2004-04-09
PL367828A1 (pl) 2005-03-07
HK1064936A1 (en) 2005-02-08
JP5014562B2 (ja) 2012-08-29
IL221708A (en) 2013-12-31
KR100938590B1 (ko) 2010-01-26
US20100291102A1 (en) 2010-11-18
IL221708A0 (en) 2012-10-31
JP5128539B2 (ja) 2013-01-23
EP1404367A2 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
HU228957B1 (en) Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
Letchworth et al. Vesicular stomatitis
DK179132B1 (en) Piscine reovirus immunogenic compositions
DK173128B1 (da) Vaccine mod det porcine reproduktions- og respirationssyndrom fremgangsmåde til fremstilling deraf samt en virus og en DNA-
HUE026089T2 (hu) NGF elleni antitestek és eljárás alkalmazásukra
Johnson et al. Molecular characterization of the glycoproteins from two warm water rhabdoviruses: snakehead rhabdovirus (SHRV) and rhabdovirus of penaeid shrimp (RPS)/spring viremia of carp virus (SVCV)
HU229368B1 (en) Novel vaccine composition
HU230199B1 (hu) A Lawsonia intracellularis tenyésztése, anti-Lawsonia intracellularis vakcinák és diagnosztikumok
HU229051B1 (en) Porcine circovirus vaccine in reconbinant poxvirus
UA124734C2 (uk) Антитіло проти с5 і його застосування
HU228121B1 (en) Corona-virus-like particles comprising functionally deleted genomes
HUE027823T2 (hu) Immunstimuláló oligonukleotidok
Ortega et al. Addicted to sugar: roles of glycans in the order Mononegavirales
UA129947C2 (uk) Спосіб застосування коагоніста gip/glp1 при діабеті
TW200918552A (en) Composition and method for immunization
Janse et al. Leukocyte subpopulations in kidney and trachea of chickens infected with infectious bronchitis virus
JP2022546856A (ja) 歯周組織由来の多分化能幹細胞を含む肥満または非アルコール性脂肪肝の予防または治療用薬学的組成物
EP0783038A1 (fr) Pseudo-particules virales recombinantes et applications vaccinales et antitumorales
Chambers A Supplement to Mr. Chambers's Cyclopædia: Or, Universal Dictionary of Arts and Sciences. In Two Volumes....
George Bovine Ephemeral Fever Virus. In
CN110526990A (zh) 靶向cd30的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
JPWO2000057695A1 (ja) 自己免疫疾患モデル動物
DK180987B1 (en) Igy antibodies for the prevention of sea lice infestation and infection
BE1000175A3 (fr) Vaccins contre le melanome.
AU664054B2 (en) Flystrike antigen and vaccine and method for preparation

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees